Investigational drug · Phase 2
BI 764524
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Retinopathy.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BI 764524"
First trial start
2024
May 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 764524", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Retinopathy
Approved drugs for the same conditions: Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 764524" as an intervention, largest first.
- A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06321302 · 175 participants (planned) · Start May 15, 2024 · Primary completion Mar 5, 2027
Drug: BI 764524; Sham comparator to BI 764524 and 1 more · For: Diabetic Retinopathy
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 90 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04424290 · 45 participants · Start Jun 12, 2020 · Primary completion Apr 28, 2023
Drug: BI 764524; Sham control of BI 764524 · For: Diabetic Retinopathy
Sites: Dothan, Alabama; Beverly Hills, California; Palo Alto, California · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Plain language summary of a study testing a new drug (BI 764524) for diabetic macular ischemia.
Jhaveri C, Newman D, Nassar K · Ther Adv Ophthalmol 2026
- [CRIMSON : A multicentre randomised, sham-controlled, double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderate to severe non-proliferative diabetic retinopathy].
Lorenz K, Peters T, Holz FG · Ophthalmologie 2026
- HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia.
Nguyen QD, Jhaveri C, Habib M, et al. · Ophthalmol Sci 2025
- HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol.
Chong V, Nguyen QD, Sepah Y, et al. · Trials 2022
Also in development for Diabetic Retinopathy
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- TarcocimabTarcocimab tedromer, KSI-301Phase 32 trials
Kodiak Sciences Inc · Wet Age-related Macular Degeneration, Diabetic Retinopathy
- PER-001 Intravitreal ImplantPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- PER-001 Intravitreal Implant - ShamPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- INV-102Phase 21 trial
Invirsa, Inc. · Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy
- VX-01Phase 21 trial
Vantage Biosciences Ltd · Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.